CoChat

Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis

Open access
Umeda, Yukihiro, Demura, Yoshiki, Morikawa, Miwa, Anzai, Masaki, Kadowaki, Maiko, Ameshima, Shingo, Tsuchida, Tatsuro, Tsujikawa, Tetsuya, Kiyono, Yasushi, Okazawa, Hidehiko, Ishizaki, Takeshi, Ishizuka, Tamotsu · 2015 · Journal of Nuclear Medicine
Cited by 62

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

UNLABELLED: The aim of this prospective study was to clarify whether dual-time-point (18)F-FDG PET imaging results are useful to predict long-term survival of idiopathic pulmonary fibrosis (IPF) patients. METHODS: Fifty IPF patients underwent (18)F-FDG PET examinations at 2 time points: 60 min (early imaging) and 180 min (delayed imaging) after (18)F-FDG injection. The standardized uptake value (SUV) at each point and retention index value (RI-SUV) calculated from those were evaluated, and then the results were compared with overall and progression-free survival. RESULTS: A multivariate Cox proportional hazards model showed higher RI-SUV and higher extent of fibrosis score as independent predictors of shorter progression-free survival. The median progression-free survival for patients with negative RI-SUV was better than that for those with positive RI-SUV (27.9 vs. 13.3 mo, P = 0.0002). On the other hand, multivariate Cox analysis showed higher RI-SUV and lower forced vital capacity to be independent predictors of shorter overall survival. The 5-y survival rate for patients with negative RI-SUV was better than that for those with positive RI-SUV (76.8% vs. 14.3%, P = 0.00001). In addition, a univariate Cox model showed that positive RI-SUV as a binary variable was a significant indicator of mortality (hazard ratio, 7.31; 95% confidence interval, 2.64-20.3; P = 0.0001). CONCLUSION: Our results demonstrate that positive RI-SUV is strongly predictive of earlier deterioration of pulmonary function and higher mortality in patients with IPF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.115.163360

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 62

Metadata

Authors
Umeda, Y., Demura, Y., Morikawa, M., Anzai, M., Kadowaki, M., Ameshima, S., Tsuchida, T., Tsujikawa, T., Kiyono, Y., Okazawa, H., Ishizaki, T., & Ishizuka, T.
Venue
Journal of Nuclear Medicine
Published
2015-09-10
Volume
56
Issue
12
Pages
1869-1875
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W2189710754
Cited by
62
References
4
FWCI
2.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.2967/jnumed.115.163360
The paper
Umeda, Y., Demura, Y., Morikawa, M., Anzai, M., Kadowaki, M., Ameshima, S., Tsuchida, T., Tsujikawa, T., Kiyono, Y., Okazawa, H., Ishizaki, T., & Ishizuka, T. (2015). Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.115.163360

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.